IGM Biosciences Inc.’s stock tumbled 14% Tuesday, as analysts weighed in with dismay on the company’s pivot away from oncology to a focus on autoimmune diseases, with at least two opting to lower their ratings.
More Stories
The S&P 500 is too tech-heavy. This alternative ETF keeps beating it.
The various stock indexing and weighting schemes will shine at different times, but some approaches are designed to be immune...
Shattuck Labs’ stock craters as biotech scraps main product candidate after failed trial
The stock hit a low of $1.37 earlier in the session, matching its record closing low that was set in...
Cannabis helping shape presidential race, with votes set for Florida, North and South Dakota
Cannabis is playing a bigger role in the U.S. presidential race than in any past campaign, with Vice President Kamala...
Apple’s stock paces Dow laggards as a rare bear voices concern on iPhone sales
A Barclays analyst says the December quarter “looks to be increasingly at risk” as iPhone demand could disappoint.
United Natural Foods ekes out an unexpected profit and stock rallies more than 20%
Company sales rise 10%, beating analyst estimates
Potential bitcoin ETF options could transform crypto trading and squeeze prices higher
Crypto bulls have expected the potential approval of options on bitcoin ETFs to allow institutional investors to execute more strategies,...